Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting

被引:50
作者
Choi, E. M. [1 ]
Lee, M. G. [2 ]
Lee, S. H. [2 ]
Choi, K. W. [1 ]
Choi, S. H. [1 ]
机构
[1] Yonsei Univ Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul, South Korea
[2] Yonsei Univ Coll Med, Dept Pharmacol, Seoul, South Korea
关键词
BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HAPLOTYPE PROFILES; POPULATIONS; PREVENTION; EFFLUX; DRUGS;
D O I
10.1111/j.1365-2044.2010.06476.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
P>We investigated whether the 2677G > T/A and 3435C > T polymorphisms of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) affect the efficacy of ondansetron to prevent postoperative nausea and vomiting. One hundred and ninety-eight patients undergoing general anaesthesia were enrolled. Thirty minutes before the end of surgery, 0.1 mg.kg-1 ondansetron was administered intravenously. The incidence of postoperative nausea and vomiting was compared between genotypes in the 2677G > T/A and 3435C > T polymorphisms of ABCB1. The incidence of postoperative nausea and vomiting was lower in patients with the 2677TT genotype (TT vs Non-TT = 25.9% vs 53.0%, p = 0.01) and 3435TT genotype (CC + CT vs TT = 52.6% vs 21.7%, p = 0.01) during the first 2 h after surgery. There were no significant differences in the incidence of postoperative nausea and vomiting between the different genotype groupings during period between 2 and 24 h after surgery. In conclusion, ABCB1 genotypes may be a clinical predictor of responsiveness for ondansetron.
引用
收藏
页码:996 / 1000
页数:5
相关论文
共 21 条
[1]   A simplified risk score for predicting postoperative nausea and vomiting -: Conclusions from cross-validations between two centers [J].
Apfel, CC ;
Läärä, E ;
Koivuranta, M ;
Greim, CA ;
Roewer, N .
ANESTHESIOLOGY, 1999, 91 (03) :693-700
[2]   Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists [J].
Babaoglu, MO ;
Bayar, B ;
Aynacioglu, AS ;
Kerb, R ;
Abali, H ;
Celik, I ;
Bozkurt, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :619-626
[3]  
Biedler A, 2004, CAN J ANAESTH, V51, P13, DOI 10.1007/BF03018540
[4]   The impact of pharmacogenomics on postoperative nausea and vomiting - Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? [J].
Candiotti, KA ;
Birnbach, DJ ;
Lubarsky, DA ;
Nhuch, F ;
Kamat, A ;
Koch, WH ;
Nikoloff, M ;
Wu, L ;
Andrews, D .
ANESTHESIOLOGY, 2005, 102 (03) :543-549
[5]   Environmental and genetic factors associated with morphine response in the postoperative period [J].
Coulbault, L ;
Beaussier, M ;
Verstuyft, C ;
Weickmans, H ;
Dubert, L ;
Trégouet, D ;
Descot, C ;
Parc, Y ;
Lienhart, A ;
Jaillon, P ;
Becquemont, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :316-324
[6]   Risk factors for postoperative nausea and vomiting [J].
Gan, Tong J. .
ANESTHESIA AND ANALGESIA, 2006, 102 (06) :1884-1898
[7]   Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting [J].
Ho, Kok-Yuen ;
Gan, Tong J. .
CURRENT OPINION IN ANESTHESIOLOGY, 2006, 19 (06) :606-611
[8]   Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: A randomized, double-blind, placebo-controlled multicenter trial [J].
Kovac, AL ;
O'Connor, TA ;
Pearman, MH ;
Kekoler, LJ ;
Edmondson, D ;
Baughman, VL ;
Angel, JJ ;
Campbell, C ;
Jense, HG ;
Mingus, M ;
Shahvari, MBG ;
Creed, MR .
JOURNAL OF CLINICAL ANESTHESIA, 1999, 11 (06) :453-459
[9]   Prevention and treatment of postoperative nausea and vomiting [J].
Kovac, AL .
DRUGS, 2000, 59 (02) :213-243
[10]   P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity [J].
Lankas, GR ;
Cartwright, ME ;
Umbenhauer, D .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 143 (02) :357-365